Evidence map›Paper›PMID 36538031›Full record

ReviewCardiovascular drugs and therapy2024

Left Ventricular Thrombus Management After Acute Myocardial Infarction in Clinical Practice: Results from LEVITATION Survey and Narrative Review.

Luca A F Di Odoardo, Matteo Bianco, Iván J Núñez Gil, Italo G Motolese, Alessandra Chinaglia, Marco Vicenzi, Stefano Carugo, Giulio G Stefanini, Enrico Cerrato

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cardiovascular drugs and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Luca A F Di Odoardo *Cardiology Unit, Cardiotoracovascular Department, Legnano Hospital, Legnano, Milan, Italy. lucadiod@inwind.it.
Matteo Bianco *Cardiology Division, San Luigi Gonzaga University Hospital, Orbassano, Turin, Italy. matteo.bianco87@gmail.com.ORCID 0000-0002-6751-6437
Iván J Núñez GilCardiovascular Institute, Hospital Clínico Universitario San Carlos, Madrid, Spain.
Italo G MotoleseCardiology Division, San Luigi Gonzaga University Hospital, Orbassano, Turin, Italy.
Alessandra ChinagliaCardiology Division, San Luigi Gonzaga University Hospital, Orbassano, Turin, Italy.
Marco VicenziDepartment of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Stefano CarugoDepartment of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Giulio G StefaniniHumanitas Clinical and Research Center IRCCS, Rozzano, Milan, Italy.
Enrico CerratoInterventional Cardiology Unit, San Luigi Gonzaga University Hospital and Infermi Hospital, Orbassano and Rivoli, Turin, Italy.
Ospedale San Luigi Gonzaga · ITUniversity of Milan · ITAzienda Ospedaliera Ospedale Civile di Legnano · ITHospital Clínico San Carlos · ESHumanitas University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLeft ventricular thrombus (LVT) after ST-elevation myocardial infarction still presents diagnostic and therapeutic challenges. The LEVITATION survey was designed to take a picture of LVT management in current clinical practice.

methodsThe survey covered diagnostic, therapeutic, and prophylactic issues and was completed by 104 European cardiac centers. Most of them (59%) were university or tertiary centers.

resultsThe survey showed anterior apical a-/dyskinesia, large MI, spontaneous echo-contrast, late presentation with delayed PCI, and TIMI flow 0-1 as the most important perceived risk factors for LVT formation. Serial ultrasound imaging is the most used tool to diagnose LVT (88% of the centers), with contrast-enhanced ultrasound and cardiac MR performed in case of poor apex visualization or spontaneous echo-contrast. One third (34%) of the centers uses prophylactic anticoagulation to prevent LVT formation. In the presence of LVT, low molecular weight heparin is the most used in-hospital therapy. At discharge, vitamin K antagonist and direct oral anticoagulants are used in 67 and 32% of the cases, respectively. Triple antithrombotic therapy with aspirin plus clopidogrel and VKA is the most used strategy at discharge (55%), whereas a single antiplatelet therapy is preferred only in the case of moderate-to-high risk of bleeding. To assess LVT total regression, half of the centers use contrast-enhanced ultrasound and/or cardiac-MR. The duration of anticoagulation is usually 3-6 months (55%), with long-term prolongation in case of LVT persistence or recurrence.

conclusionThe survey has depicted for the first time the current real-world management of this neglected topic and has highlighted several grey zones that are still present and not supported by evidence.

Indexed as

AnticoagulantsThrombosisEuropeFibrinolytic AgentsHealth Care SurveysHeart DiseasesHeart VentriclesHumansPlatelet Aggregation InhibitorsPractice Patterns, Physicians'Risk FactorsST Elevation Myocardial InfarctionTreatment OutcomeAnticoagulantsFibrinolytic AgentsPlatelet Aggregation InhibitorsAcute cardiac careAntithrombotic therapyDirect oral anticoagulant (DOAC)Left ventricular thrombusST-elevation myocardial infarction (STEMI)Survey

Identifiers

PMID36538031
OpenAlexW4312018865

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.